A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

StatusCompleted
PhasePhase 3
SponsorTakeda
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Primary completion date changed from estimate of Dec 31, 2026 to Jul 22, 2026
    • Study sites: 12 to 11
    • Eligibility criteria expanded, about 34 words
    • Secondary endpoints: details revised at 10 of 18 entries
  2. Site details revised at 1 of 12 sitesv6
  3. Site contacts updated at 1 of 12 sitesv5
  4. Study sites: 1 to 12
    • Primary and study completion dates: Feb 5, 2027 to Dec 31, 2026
    v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 14, 2025 to Dec 16, 2024
    • Site details revised
    v3
  6. Study Status, Referencesv2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Takeda
222 trials monitored
See 14 trials at risk
The main aim of this study is to learn how safe maribavir is in Chinese adults who have undergone hematopoietic stem cell or organ transplantation and have a cytomegalovirus (CMV) infection and how well they tolerate treatment with maribavir. Other aims are to see how effective maribavir is in treating CMV infection and getting rid of the symptoms, the recurrence rate of CMV infection after treatment with maribavir and if the treatment is required again. Researchers will also check for changes (mutations) occurring in the virus which may cause treatment with maribavir to no longer work well or to not work at all (resistance to maribavir). The participants will be treated with maribavir for 8 weeks. During the study, participants will visit their study clinic 18 times.
Trial Details
NCT Number NCT06439342
Lead Sponsor Takeda
Conditions
(from sponsor)		 Cytomegalovirus (CMV)
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov